240 related articles for article (PubMed ID: 21724680)
1. Relation between thyroid-stimulating hormone and the occurrence of cardiovascular events and mortality in patients with manifest vascular diseases.
Westerink J; van der Graaf Y; Faber DR; Spiering W; Visseren FL;
Eur J Prev Cardiol; 2012 Aug; 19(4):864-73. PubMed ID: 21724680
[TBL] [Abstract][Full Text] [Related]
2. The risk of general and abdominal adiposity in the occurrence of new vascular events and mortality in patients with various manifestations of vascular disease.
Kanhai DA; Kappelle LJ; van der Graaf Y; Uiterwaal CS; Visseren FL;
Int J Obes (Lond); 2012 May; 36(5):695-702. PubMed ID: 21712810
[TBL] [Abstract][Full Text] [Related]
3. Thyroid function, cardiovascular events, and mortality in diabetic hemodialysis patients.
Drechsler C; Schneider A; Gutjahr-Lengsfeld L; Kroiss M; Carrero JJ; Krane V; Allolio B; Wanner C; Fassnacht M
Am J Kidney Dis; 2014 Jun; 63(6):988-96. PubMed ID: 24315768
[TBL] [Abstract][Full Text] [Related]
4. The prevalence of obesity-related hypertension and risk for new vascular events in patients with vascular diseases.
Vernooij JW; van der Graaf Y; Visseren FL; Spiering W;
Obesity (Silver Spring); 2012 Oct; 20(10):2118-23. PubMed ID: 22517513
[TBL] [Abstract][Full Text] [Related]
5. Association Between Serum Thyrotropin Levels and Mortality Among Euthyroid Adults in the United States.
Inoue K; Tsujimoto T; Saito J; Sugiyama T
Thyroid; 2016 Oct; 26(10):1457-1465. PubMed ID: 27539006
[TBL] [Abstract][Full Text] [Related]
6. The relation between thyroid-stimulating hormone and measures of adiposity in patients with manifest vascular disease.
Westerink J; van der Graaf Y; Faber DR; Visseren FL;
Eur J Clin Invest; 2011 Feb; 41(2):159-66. PubMed ID: 21039443
[TBL] [Abstract][Full Text] [Related]
7. The separate and combined effects of adiposity and cardiometabolic dysfunction on the risk of recurrent cardiovascular events and mortality in patients with manifest vascular disease.
van der Leeuw J; van der Graaf Y; Nathoe HM; de Borst GJ; Kappelle LJ; Visseren FL;
Heart; 2014 Sep; 100(18):1421-9. PubMed ID: 24817441
[TBL] [Abstract][Full Text] [Related]
8. Microvesicle protein levels are associated with increased risk for future vascular events and mortality in patients with clinically manifest vascular disease.
Kanhai DA; Visseren FL; van der Graaf Y; Schoneveld AH; Catanzariti LM; Timmers L; Kappelle LJ; Uiterwaal CS; Lim SK; Sze SK; Pasterkamp G; de Kleijn DP;
Int J Cardiol; 2013 Oct; 168(3):2358-63. PubMed ID: 23484740
[TBL] [Abstract][Full Text] [Related]
9. Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study.
Achterberg S; Cramer MJ; Kappelle LJ; de Borst GJ; Visseren FL; van der Graaf Y; Algra A;
Eur J Cardiovasc Prev Rehabil; 2010 Aug; 17(4):424-30. PubMed ID: 20555265
[TBL] [Abstract][Full Text] [Related]
10. The risk of resting heart rate on vascular events and mortality in vascular patients.
Bemelmans RH; van der Graaf Y; Nathoe HM; Wassink AM; Vernooij JW; Spiering W; Visseren FL;
Int J Cardiol; 2013 Sep; 168(2):1410-5. PubMed ID: 23305859
[TBL] [Abstract][Full Text] [Related]
11. Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults.
Tseng FY; Lin WY; Lin CC; Lee LT; Li TC; Sung PK; Huang KC
J Am Coll Cardiol; 2012 Aug; 60(8):730-7. PubMed ID: 22726629
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular events in thyroid disease: a population based, prospective study.
Schultz M; Kistorp C; Raymond I; Dimsits J; Tuxen C; Hildebrandt P; Faber J
Horm Metab Res; 2011 Aug; 43(9):653-9. PubMed ID: 21823062
[TBL] [Abstract][Full Text] [Related]
13. Thyroid function and the risk of coronary heart disease: 12-year follow-up of the HUNT study in Norway.
Asvold BO; Bjøro T; Platou C; Vatten LJ
Clin Endocrinol (Oxf); 2012 Dec; 77(6):911-7. PubMed ID: 22724581
[TBL] [Abstract][Full Text] [Related]
14. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death.
Rodondi N; Newman AB; Vittinghoff E; de Rekeneire N; Satterfield S; Harris TB; Bauer DC
Arch Intern Med; 2005 Nov; 165(21):2460-6. PubMed ID: 16314541
[TBL] [Abstract][Full Text] [Related]
15. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis.
Singh S; Duggal J; Molnar J; Maldonado F; Barsano CP; Arora R
Int J Cardiol; 2008 Mar; 125(1):41-8. PubMed ID: 17434631
[TBL] [Abstract][Full Text] [Related]
16. Hyperthyroidism, Hypothyroidism, and Cause-Specific Mortality in a Large Cohort of Women.
Journy NMY; Bernier MO; Doody MM; Alexander BH; Linet MS; Kitahara CM
Thyroid; 2017 Aug; 27(8):1001-1010. PubMed ID: 28578598
[TBL] [Abstract][Full Text] [Related]
17. Carotid intima-media thickness and the risk of new vascular events in patients with manifest atherosclerotic disease: the SMART study.
Dijk JM; van der Graaf Y; Bots ML; Grobbee DE; Algra A
Eur Heart J; 2006 Aug; 27(16):1971-8. PubMed ID: 16835264
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of abnormal thyrotropin concentrations measured by a sensitive assay in patients with type 2 diabetes mellitus.
Celani MF; Bonati ME; Stucci N
Diabetes Res; 1994; 27(1):15-25. PubMed ID: 7648793
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of thyroid disease in patients with obstructive sleep apnea.
Bahammam SA; Sharif MM; Jammah AA; Bahammam AS
Respir Med; 2011 Nov; 105(11):1755-60. PubMed ID: 21820299
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.
Sumner G; Salehian O; Yi Q; Healey J; Mathew J; Al-Merri K; Al-Nemer K; Mann JF; Dagenais G; Lonn E;
J Cardiovasc Electrophysiol; 2009 Jul; 20(7):781-7. PubMed ID: 19298567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
